Tesamorelin Visceral Fat Reduction: Meta-Analysis of Clinical Trials
A meta-analysis confirms tesamorelin's targeted visceral fat reduction effects across multiple trial populations.
What Is Tesamorelin?
Tesamorelin (brand name Egrifta SV) is the only FDA-approved GHRH (growth hormone-releasing hormone) analog, indicated for reduction of excess visceral abdominal fat in HIV patients with lipodystrophy. It stimulates endogenous growth hormone production, which preferentially mobilizes visceral adipose tissue.
Its FDA approval status makes it unique among growth hormone secretagogues, providing a regulatory precedent for peptide therapy in metabolic conditions.
Dosing Protocol
Tesamorelin is typically administered at 2 mg subcutaneously once daily. The injection is given in the abdominal area. Use our tesamorelin dosage calculator for exact reconstitution instructions. IGF-1 levels should be monitored to ensure the growth hormone axis is not over-stimulated.
Clinical Evidence
Tesamorelin has the strongest clinical evidence of any growth hormone secretagogue, with Phase 3 trial data supporting its use for visceral fat reduction. The meta-analysis across trials shows consistent 10-15% visceral fat reductions.
📊 Dosage Calculator & Protocol Chart
Use our free Tesamorelin dosage calculator to plan your protocol:
👉 Tesamorelin Dosage Calculator — Calculate exact dosing, reconstitution ratios, and injection volumes.
👉 Full Dosing Guide & Protocol Chart — Complete protocol with weekly titration schedule, side effect management, and cycle recommendations.
Important Disclaimer
This article is for educational and research purposes only. Peptides discussed may not be FDA-approved for all uses described. Always consult with a qualified healthcare provider before starting any peptide protocol. The information provided here is synthesized from published research, clinical trial data, and community discussions.
Keywords: tesamorelin, visceral fat, GHRH, growth hormone, lipodystrophy
Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content